Rheumatoid arthritis Market forecast to 2027 detailed in new research report

Pune, India, 2017-Jun-29 — /EPR Network/ —

Market Scenario:

Globally the market for rheumatoid arthritis is increasing rapidly. The major factor that derives the growth of rheumatoid arthritis is the increasing aging population. Furthermore some evidence suggests that people who smoke are at an increased risk of developing rheumatoid arthritis. Rheumatoid Arthritis Market is expected to grow at the rate of about XX% CAGR from 2016 to 2022.

The hottest trend in the market

The therapeutic treatment of rheumatoid arthritis (RA) has been affected emphatically amid the previous decade by the recognition that numerous patients develop joint damage within the first year of disease. This perception has motivated rheumatologists to start disease-modifying antirheumatic drugs (DMARDs) early in the disease course. This trend has been coordinated by the expanded utilization of combination DMARD treatment, with the mean to boost control of the signs and side effects of RA and point of confinement the development of joint injury.

Key Players for Rheumatoid Arthritis Market:                                            

  • Pfizer Inc (U.S),
  • Eli Lilly and company (U.S),
  • Bristol-Myers Squibb Company (U.S),
  • Hoffmann-La Roche Ltd (switzerland),
  • Novartis AG (switzerland),
  • Vertex Pharmaceuticals Incorporated (U.S),
  • Sanofi (France),
  • AstraZeneca (U.K).

Request a Sample Copy @ https://www.marketresearchfuture.com/sample_request/1658

Segments:                                                                                                                                       

On the basis of drug type

  • Non-steroidal anti-inflammatory drug type (NSAID)
  • Steroids
  • Disease-modifying anti-rheumatic drug type (DMARDs)
  • Biologic agents.

On the basis of treatment

  • Synovectomy
  • Tendon repair
  • Joint fusion
  • Total joint replacement.

On the basis of diagnosis

  • C – reactive protein (CRP) Test
  • CCP
  • ESR (Erythrocyte Sedimentation Rate) Test
  • Synovial Fluid Analysis.

Among the Rheumatoid arthritis drug type, DMARD is compositing the growth of the market

Currently rheumatoid arthritis drug type such as DMARD as of now are been utilized to prevent rheumatoid arthritis. It is projected to the largest-share holding segment of the market from the period of 2011 to 2022. Further it also has promising growth rate during the forecast period from 2016 to 2022.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. Our market research studies by products, services, technologies, applications, end users, and market players for global, regional, and country level market segments, enable our clients to see more, know more, and do more, which help to answer all their most important questions.

Contact:

Akash Anand,

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune – 411028

Maharashtra, India

+1 646 845 9312

Email: akash.anand@marketresearchfuture.com

Matched content

Editor’s pick